NeurologyLive® Friday 5 — January 27, 2023

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive^®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: 5 FDA Pending Approvals in Neurology to Look for in 2023

There are several upcoming treatment approvals to come in 2023 ranging from neurological specialties in movement disorders, neuromuscular, headache and migraine, and sleep disorders. As there is so much happening constantly in the clinical drug pipeline, keeping up with the latest approvals might be a challenge. Take a look at 5 of the most-anticipated FDA pending approvals expected in 2023 that neurological researchers and clinicians should keep an eye out on.

2: Peer Exchange: Treatment Pipeline for Alzheimer’s Disease

In episode 12 of this Peer Exchange, the panel of experts in dementia discusses drug candidates and various mechanisms of actions that are currently under evaluation for Alzheimer’s disease. The NeurologyLive^® series panel features Marwan Sabbagh, MD; Alireza Atri, MD, PhD; Sharon Cohen, MD, FRCPC; and Eric McDade, DO.

3: NeuroVoices: Darin Okuda, MD, FAAN, FANA, on Early Detection of RIS and Significance of ARISE Study Findings

In the latest edition of our in-depth Q&A series, the director of Neuroinnovation and Multiple Sclerosis & Neuroimmunology Imaging Program at UT Southwestern Medical Center provided insight on the promising future of treating radiologically isolated syndrome at its earliest stages.

4: Episode 81: Robert Hauser, MD, on PD Care and IPX203

In episode 81 of NeurologyLive^®'s Mind Moments^® podcast, brings you an exclusive interview with Robert Hauser, MD, director of the Parkinson’s and Movement Disorders Center at the University of South Florida. He spoke about the current state of therapeutics in Parkinson disease, some of the lingering challenges in day-to-day management, the promise of novel agents in development such as IPX203, and more.

5: MDA’s Focus on Better Access for Patients With Neuromuscular Disorders: Paul Melmeyer

Ahead of the 2023 MDA Conference, which will be held from March 19-22, 2023, in Dallas, Texas, the vice president of public policy and advocacy at the Muscular Dystrophy Association provided an overview of the current state of access and the need for more advocates in neuromuscular disease. [WATCH TIME: 14 minutes]

—————————————————

Nominations for Giants of Multiple Sclerosis^® are open! This premier neuroscience award program celebrates pioneers, innovators, and future generations of leaders for their remarkable achievements in multiple sclerosis. Nominations close on January 31, 2023!

Nominate: neurologylive.com/Giants-of-MS